Beyond ALT/AST — Liver-Specific Hepatotoxicity Biomarkers

ALT and AST have served as standard liver function markers for decades — but both have fundamental limitations in drug safety assessment. ALT is predominantly hepatic but also expressed in kidney and skeletal muscle. AST is widely distributed across liver, heart, skeletal muscle, kidney, brain, and red blood cells — an elevated AST alone cannot distinguish liver from muscle or cardiac injury. Both rise only after significant hepatocellular damage and can remain elevated for days after the initial insult — providing a delayed, non-specific signal. The PSTC (Predictive Safety Testing Consortium), in collaboration with the FDA and EMA, recognized Arginase-1 and GST-α as liver-specific biomarkers that provide earlier, more specific detection of hepatocellular injury. Arginase-1 is a urea cycle enzyme expressed almost exclusively in hepatocytes; its appearance in circulation directly reflects hepatocyte damage, not muscle or cardiac injury. GST-α is a small cytoplasmic detoxification enzyme released rapidly into circulation upon hepatocellular membrane damage — often hours before ALT/AST elevation in preclinical models.

Liver Injury Biomarkers — Mechanisms & Advantages

  • Arginase-1 (ARG1): liver-specific urea cycle enzyme expressed in periportal and perivenous hepatocytes. PSTC/FDA-recognized for preclinical hepatotoxicity. Released exclusively from damaged hepatocytes — unlike ALT/AST, elevation unambiguously indicates liver injury. Measured in the Rat Liver Injury Panel.
  • α-Glutathione S-Transferase (GST-α): detoxification enzyme highly expressed in hepatocyte cytoplasm. Small molecular size (50 kDa) enables rapid release into circulation upon membrane damage — often hours before ALT/AST. PSTC/FDA-recognized. Provides earlier detection than transaminases in published preclinical models.
  • Liver specificity vs. ALT/AST: ALT can be elevated from muscle injury; AST is ubiquitous. Arginase-1 is liver-exclusive — when combined with GST-α in a single multiplex measurement, the combination provides both liver specificity (ARG1) and early detection (GST-α) that ALT/AST cannot match.
  • 250-fold dynamic range: published PSTC model data demonstrated up to 250-fold elevation of ARG1 and GST-α at 24 hours post-hepatotoxicant, with return to baseline over 4 days — providing quantitative, temporal injury data for dose-response and time-course analysis.